Derisking Biomanufacturing: Why A CDMO In Poland Might Be Your Secret Weapon

By Nigel Stapleton, VP of Business Development - Head of Europe, and Slawomir Jaros, Chief Scientific and Quality Affairs Officer

As biomanufacturing becomes an increasingly global pursuit, many drug developers are opting to partner with CDMOs located in other countries. The decision to partner with an international CDMO comes with inherent pros and cons depending on your chosen CDMO and where they are located. To help protect the IP of drug developers, enhance innovation, and improve collaboration between sponsors, CDMOs, and regulators, both the US and EU are opting to implement strategic biomanufacturing legislation and initiatives.

While you assess potential partnerships, consider how geopolitical factors relevant to your location and a CDMO’s could impact the success of your drug development. Furthermore, consider which qualities in a partner are must-haves, including cost, efficiency, and previous experience. Download the full article to learn more about these geopolitical shifts and explore the possibilities of one lesser-known destination for outsourcing: Poland.